<PAGE> 1

                              UNITED STATES
                     SECURITIES AND EXCHANGE COMMISSION
                          WASHINGTON, D.C. 20549

                               FORM 10-QSB


(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2005.

OR

[ ]TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 FOR THE TRANSITION FROM _______ TO ________.

                    COMMISSION FILE NUMBER 000-27421

                   EMERGENCY FILTRATION PRODUCTS, INC.
          ------------------------------------------------------
          (Exact name of registrant as specified in its charter)

              NEVADA                              87-0561647
   --------------------------------           -------------------
   (State or other jurisdiction of             (I.R.S. Employer
    incorporation or organization)            Identification No.)

    175 Cassia Way, Suite A115
           Henderson, Nevada                        89014
----------------------------------------          ---------
(Address of principal executive offices)          (Zip code)

Issuer's telephone number: (702) 558-5164

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.  Yes [X]    No [ ]

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Exchange Act Rule 12b-2). Yes [ ]    No [X]

Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).  Yes [ ]    No [X]

State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date:

At October 31, 2005, there were outstanding 37,489,948 shares of the
Registrant's Common Stock, $.001 par value.

Transitional Small Business Disclosure Format: Yes [ ]   No [X]

<PAGE>
<PAGE> 2
PART I

                             FINANCIAL INFORMATION

                                  Item 1.

TABLE OF CONTENTS
                                                                 Page
                                                                 ----
Part I Financial Information

Item 1. Financial Statements

Balance Sheets
September 30, 2005 (Unaudited) and December 31, 2004.........       3

Statements of Operations (Unaudited)for the three months and
 nine months ended September 30, 2005 and 2004...............       4

Statements of Cash Flows (Unaudited)for the nine months ended
 September 30, 2005 and 2004.................................       5

Notes to the Financial Statements............................       6

Item 2. Management's Discussion and Analysis of Financial
        Condition and Results of Operations...................     10

Item 3. Controls and Procedures...............................     16

Part II Other Information

Item 1. Legal Proceedings.....................................     16

Item 2. Unregistered Sales of Equity Securities
         and Use of Proceeds..................................     16

Item 3. Defaults by the Company on its
         Senior Securities....................................     16

Item 4. Submission of Matter to a Vote
         Of Security Holders..................................     16

Item 5. Other Information .....................................    16

Item 6. Exhibits ..............................................    17

Signatures.....................................................    17




<PAGE>
<PAGE> 3

EMERGENCY FILTRATION PRODUCTS, INC.
Balance Sheets
September 30, 2005 and December 31, 2004
                                                  September 30,  December 31,
                                                      2005          2004
                                                   (Unaudited)
                                                   -----------   -----------
ASSETS

CURRENT ASSETS
 Cash and cash equivalents                        $    200,847  $    438,151
 Accounts receivable, net of an allowance for
  doubtful accounts of $8,500                           20,654         8,071
 Prepaid expenses and other                             24,160        40,342
 Inventory                                             185,815       183,275
                                                   -----------   -----------
                                                       431,476       669,839
                                                   -----------   -----------
PROPERTY AND EQUIPMENT, net of accumulated
 depreciation of $200,004 and $182,835                  89,140        66,181
                                                   -----------   -----------
OTHER ASSETS
 Patents and acquired technology, net of
  accumulated amortization of $198,837 and
  $143,097                                             915,950       971,689
 Deposits and other assets                               6,111         3,462
                                                   -----------   -----------
                                                       922,061       975,151
                                                   -----------   -----------
                                                  $  1,442,677   $ 1,711,171
                                                   ===========   ===========
LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
 Accounts payable, related parties                $    133,237   $   168,972
 Accounts payable, other                                64,341        36,522
 Accrued expenses                                      189,749        89,761
 Notes payable                                           9,794        25,479
                                                   -----------   -----------
                                                       397,121       320,734
                                                   -----------   -----------
STOCKHOLDERS' EQUITY
 Common stock, par value $0.001; authorized
  50,000,000 shares; 34,507,348 and
  33,687,848 shares issued and outstanding              34,507        33,688
 Additional paid-in capital                         11,453,479    11,210,673
 Deferred compensation                                 (48,000)      (68,000)
 Accumulated other comprehensive income                (11,331)       (7,910)
 Deficit                                           (10,383,099)   (9,778,014)
                                                   -----------   -----------
                                                     1,045,556     1,390,437
                                                   -----------   -----------
                                                   $ 1,442,677   $ 1,711,171
                                                   ===========   ===========


The accompanying notes are an integral part of these financial statements.

<PAGE>
<PAGE> 4

EMERGENCY FILTRATION PRODUCTS, INC.
Statements of Operations
For the Three Months and Nine Months Ended September 30, 2005 and 2004
(Unaudited)

                      For the Three Months Ended   For the Nine Months Ended
                             September 30,                September 30,
                           2005          2004          2005          2004
                       -----------   -----------   -----------   -----------
NET SALES             $     54,149  $     62,611  $    119,960  $    387,782
                       -----------   -----------   -----------   -----------
COSTS AND EXPENSES
 Cost of sales              39,111        37,495        79,720       252,298
 Depreciation and
  amortization              24,113        26,019        74,268        83,003
 Research and
  development                2,750             -         9,750             -
 Loss on vacating
  lease                          -             -             -         8,418
 Bad debts                       -        21,517             -        22,017
 Selling, general and
  administrative           255,559       455,236       620,807       972,157
                       -----------   -----------   -----------   -----------
                           321,533       540,267       784,545     1,337,893
                       -----------   -----------   -----------   -----------
LOSS FROM OPERATIONS      (267,384)     (477,656)     (664,585)     (950,111)
                       -----------   -----------   -----------   -----------
Other income(expense)

 Interest expense             (208)       (1,203)       (1,470)      (43,830)
 Settlement gain            60,970             -        60,970             -
                       -----------   -----------   -----------   -----------
                            60,762        (1,203)       59,500       (43,830)
                       -----------   -----------   -----------   -----------

NET LOSS              $   (206,622) $   (478,859) $   (605,085) $   (993,941)
                       ===========   ===========   ===========   ===========
BASIC AND DILUTED
 LOSS PER SHARE       $      (0.01) $      (0.02) $      (0.02) $      (0.04)
                       ===========   ===========   ===========   ===========
WEIGHTED AVERAGE
 NUMBER OF COMMON
 SHARES OUTSTANDING     34,507,348    27,881,158    34,342,328    27,543,287
                       ===========   ===========   ===========   ===========






The accompanying notes are an integral part of these financial statements.



<PAGE>
<PAGE> 5

EMERGENCY FILTRATION PRODUCTS, INC.
Statements of Cash Flows
For the Nine Months Ended September 30, 2005 and 2004
(Unaudited)
                                                     2005           2004
                                                 ------------   ------------
CASH FLOWS FROM OPERATING ACTIVITIES:
 Net loss                                       $    (605,085) $    (993,941)
 Adjustments to reconcile net loss to net
  cash used in operating activities:
  Depreciation                                         18,528         29,637
  Amortization of patent costs                         55,740         53,366
  Bad debts                                                 -         22,017
  Common stock issued for services                     20,000        278,010
  Settlement gain                                     (60,970)             -
 Changes in operating assets and liabilities:
  Accounts receivable                                 (12,584)       (13,310)
  Prepaid expenses and other                           30,794         65,032
  Inventory                                            (2,540)        21,858
  Deposits                                             (2,649)         8,268
  Accounts payable, including to
   related parties                                     55,454        226,391
  Accrued expenses                                     99,988         14,541
                                                 ------------   ------------
   Net Cash Used In Operating Activities             (403,324)      (288,131)
                                                 ------------   ------------
CASH FLOWS FROM INVESTING ACTIVITIES:
 Acquisition of property and equipment                (43,887)             -
                                                 ------------   ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
 Common stock issued through exercise
  of warrants for cash                                243,625        852,193
 Payment on notes payable                             (30,297)       (50,712)
                                                 ------------   ------------
   Net Cash Provided by Financing Activities          213,328        801,481

EFFECT OF CURRENCY EXCHANGE RATE CHANGES
 ON CASH AND CASH EQUIVALENTS                          (3,421)          (883)
                                                 ------------   ------------
NET INCREASE(DECREASE) IN CASH AND
 CASH EQUIVALENTS                                    (237,304)       512,467

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD      438,151        148,501
                                                 ------------   ------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD      $     200,847  $     660,968
                                                 ============   ============











The accompanying notes are an integral part of these financial statements.

<PAGE>
<PAGE> 6

EMERGENCY FILTRATION PRODUCTS, INC.
Notes to the Financial Statements
September 30, 2005 and December 31, 2004

NOTE 1 - BASIS OF PRESENTATION

The interim financial information included herein is unaudited and has been
prepared consistent with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-QSB and Item 310(b)
of Regulation S-B.  Accordingly, these financial statements do not include all
information required by generally accepted accounting principles for annual
financial statements.  These statements should be read in conjunction with the
audited financial statements and notes thereto included in the Company's
annual report on Form 10-KSB for the year ended December 31, 2004, from which
the balance sheet information as of that date is derived.  These interim
financial statements contain all adjustments necessary in the opinion of
management for a fair statement of results for the interim periods presented.

The results of operations for the three months and nine months ended September
30, 2005, are not necessarily indicative of the results to be expected for the
full year.

Certain prior period amounts have been reclassified to conform with the
current period presentation.

NOTE 2 - LOSS PER SHARE

Following is information relative to the computation of basic and diluted loss
per share for the three months and nine months ended September 30, 2005 and
2004:

                                     For the Three Months Ended
                                             September 30,
                                          2005          2004
                                      -----------   -----------
Net loss                             $   (206,622) $   (478,859)
                                      ===========   ===========
Weighted average shares                34,507,348    27,881,158
                                      ===========   ===========
Basic and diluted loss per share     $      (0.01) $      (0.02)
                                      ===========   ===========

                                     For the Nine Months Ended
                                            September 30,
                                          2005          2004
                                      -----------   -----------
Net loss                             $   (605,085) $   (993,941)
                                      ===========   ===========
Weighted average shares                34,342,328    27,543,287
                                      ===========   ===========
Basic and diluted loss per share     $      (0.02) $      (0.04)
                                      ===========   ===========

Weighted average shares issuable upon the exercise of stock warrants were not
included in the foregoing calculations because they are antidilutive.

<PAGE>
<PAGE> 7

EMERGENCY FILTRATION PRODUCTS, INC.
Notes to the Financial Statements
September 30, 2005 and December 31, 2004

NOTE 3 - GOING CONCERN CONTINGENCY

The Company's financial statements are prepared using accounting principles
applicable to a going concern. Those principles contemplate the realization of
assets and liquidation of liabilities in the normal course of business.  The
Company has incurred negative cash flow from operations and significant
losses, which have resulted in a deficit of $10,383,099 at September 30, 2005.

Consequently, the Company's ability to continue as a going concern may be
dependent upon the success of management's ongoing business plans which, as
explained below, include a) continued product development efforts, b)
continuing efforts to increase its product sales in the U.S. and
internationally, and c) seeking additional equity financing, if needed to
sustain operations until revenues are adequate to cover its costs and
expenses.

The Company has recently increased its production capabilities for its
environmental masks due to an increase in demand and plans to further increase
its production capacity as demand dictates.  The Company expects its product
sales for this environmental mask to significantly increase in the near
future.

In late 2004, the Company was awarded a grant from the U.S. military to
develop a testing protocol for its nano-enhanced filter media, which was
completed in May 2005.  The funds from this grant are expected to be paid
directly to the testing facility during the fourth quarter of 2005.  As a
result of these successful tests, the U.S. military is expected to begin
introducing the Company's technology to companies that manufacture filters for
various military applications with the aim of having them incorporate the
technology in their filter applications.

Throughout 2004 and 2005, the Company had been in discussions with a large
Asian multinational company, involved in chemical and related businesses,
including air filtration, that had shown interest in a possible distribution
agreement for the Company's air filter products and technologies in Japan.
During October 2004, the Company announced that this large Asian company
obtained a Certificate of Import and a Certificate of Sale from the Koseisho
(the Japanese Ministry of Health and Welfare, akin to the United States Food
and Drug Administration) to immediately begin importing and selling certain of
the Company's emergency respiration products in Japan.  On December 28, 2004,
the Company entered into an exclusive, long-term agreement with this large
Asian company whereby the Asian company will distribute certain of the
Company's products in Japan, once their final assessment of the overall market
for the products is completed.  The Company has provided the Asian company
with samples that incorporated certain modifications that were requested in
order to conform the Company's products to Japanese standards.  This process
has taken longer than originally expected, but the Company is now awaiting
final validation and confirmation of the last round of modifications to the
products, following which the Company expects to commence commercial shipments
to Japan.   The agreement terminates on May 31, 2008, but can be extended for
an additional three-year period.  The agreement also allows for the Asian
company to form sub-distribution agreements with other medical product
companies, with the Company's approval, to promote the sale of the Company's
products in Japan.


<PAGE>
<PAGE> 8

EMERGENCY FILTRATION PRODUCTS, INC.
Notes to the Financial Statements
September 30, 2005 and December 31, 2004

NOTE 3 - GOING CONCERN CONTINGENCY (Continued)

The Company was able to raise $243,625 in additional funds during the nine
months ended September 30, 2005, through the exercise of outstanding warrants
to sustain operations.  An additional $886,900 was raised through the exercise
of additional outstanding warrants subsequent to September 30, 2005. These
funds have been used to retire previously outstanding debt, to acquire
additional molds for the Company's products and for ongoing working capital.

It is management's intent to seek to create additional revenues through the
development and sales of its emergency respiration equipment and its
environmental masks, as discussed above.  However, management can offer no
assurance with respect to its ability to create additional revenues, obtain
additional equity financing, if needed, or otherwise execute its long-term
business plans.

The accompanying financial statements do not include any adjustments relating
to the recoverability and classification of asset carrying amounts or the
amount and classification of liabilities that might result from the outcome of
this uncertainty.

NOTE 4 - STOCK WARRANTS OUTSTANDING

The Company has granted warrants to purchase common stock in conjunction with
certain stock issuances for cash.  A summary of the status of the Company's
stock warrants as of September 30, 2005, and changes during the nine months
then ended, are presented below:

                                                 Weighted      Weighted
                                                  average       average
                                                 exercise     grant date
                                   Warrants        price      fair value
                                  -----------   -----------   -----------
Outstanding, December 31, 2004      4,633,550   $      0.30   $         -
Exercised                            (819,500)         0.30             -
                                  -----------   -----------   -----------
Outstanding, September 30, 2005     3,814,050   $      0.30   $         -
                                  ===========   ===========   ===========

The outstanding warrants at September 30, 2005, are as follows:

               Number of           Exercise               Expiration
               warrants             price                    date
            -------------        ------------            ------------
                  100,000        $       0.25          April 11, 2006
                  662,800                0.25          April 23, 2006
                  226,250                0.50          May 27, 2006
                2,825,000                0.30          September 30, 2006



<PAGE>
<PAGE> 9

EMERGENCY FILTRATION PRODUCTS, INC.
Notes to the Financial Statements
September 30, 2005 and December 31, 2004

NOTE 5 - SETTLEMENT GAIN

During the three months ended September 30, 2005, the Company completed a
settlement to resolve two related legal actions.  The two actions were
described more fully in the Company's quarterly report on Form 10-QSB for the
period ended June 30, 2005. The settlement provided for the limited mutual
release of all parties for claims which could have been asserted, arising from
or related to, directly or indirectly, the legal actions.  The parties further
agreed to dismiss all claims pending in the actions with prejudice.
Accordingly, the Company recorded a settlement gain of $60,970 during the
three months ended September 30, 2005 related to this release of all claims
pending in the actions.

NOTE 6 - SUBSEQUENT EVENT

Subsequent to September 30, 2005, the Company issued the following shares of
common stock:

         - 2,982,000 shares through the exercise of common stock warrants at
           prices ranging from $0.25 to $0.50 per share, for total cash
   proceeds of $886,900.
         - 236,840 shares valued at $0.38 per share issued to the Company's
           directors in full settlement of accrued and unpaid directors fees
         totaling $90,000.
         - 1,025,000 shares valued at $0.88 per share issued to certain of the
           Company's officers and consultants in full settlement of unpaid
       wages, bonuses and consulting fees totaling $902,000.









<PAGE>
<PAGE> 10
                                ITEM 2
Management's Discussion and Analysis of Financial Condition and Results of
Operations

Cautionary Statement Regarding Forward-looking Statements
---------------------------------------------------------
This report may contain "forward-looking" statements.  Examples of forward-
looking statements include, but are not limited to: (a) projections of
revenues, capital expenditures, growth, prospects, dividends, capital
structure and other financial matters; (b) statements of plans and objectives
of our management or Board of Directors; (c) statements of our future economic
performance; (d) statements of assumptions underlying other statements and
statements about us and our business relating to the future; and (e) any
statements using the words "anticipate," "expect," "may," "project," "intend"
or similar expressions.

Overview
--------
The Company is in the business of producing masks and filters for medical
devices that are designed to reduce the possibility of transmission of
contagious diseases.  The Company is also a distributor of a blood clotting
device for surgery, trauma and burn wound management.

Since its inception, the Company has been involved in the development of its
technology.  During this time, revenues have not been adequate to cover
operating expenses. Without adequate revenues to offset expenditures, the
Company has reported a loss in each of its years of existence.  To date, the
Company has funded itself by way of a series of private equity placements.  As
of the end of fiscal 2004, the Company had offset its accumulated deficit in
this manner. The most valuable asset of the Company is its intellectual
property and technology.  The Company has acquired the rights to certain
intellectual property, which property includes title to the patent on a
component of an emergency CPR assistance device, called a dual-filtered vapor
isolation valve and the rights to certain other technologies related to
environmental masks.  Rights pertaining thereto include the right to maintain,
sell and improve the devices, and to license those rights.  Although the
Company believes its technology to be very valuable in the economic sense,
this value is not quantified as such on the Company's balance sheet.

Results of Operations
---------------------
Nine Months Ended September 30, 2005 compared with 2004
-------------------------------------------------------
Revenues:  During the nine months ended September 30, 2005, the Company
experienced a decrease in revenues compared to the nine months ended September
30, 2004 of approximately $268,000 or 69% primarily due to the reduction in
sales of the environmental masks. This reduction in sales of the environmental
masks was due to the gradual decline in the demand for the masks in the Asian
markets and increased competition.  However, the Company expects the demand
for the environmental masks to increase in the near future due to continuing
and expected virus outbreaks such as SARS and Avian Influenza (Bird Flu).
Environmental masks sales were showing a strong improvement at the end of the
quarter ended September 30, 2005 and the Company is currently increasing its
production facilities in order to meet the expected increase in the demand for
this product. The Company plans to further increase the production facilities
capacity as demand dictates.  The Company expects that sales of the
environmental mask will significantly increase in the near future.  The
Company has also recently purchased four additional filter cutting and sealing
machines that will enable it to rapidly produce filters and incorporate
nanoparticles in its filters at its own facilities.

<PAGE>
<PAGE> 11

In addition, during March, 2005, the Company entered into a non-exclusive
distribution agreement with a California based company to distribute the
Company's environmental masks to both retail and wholesale market segments in
the United States and internationally.  The distributor is working on a
marketing campaign for the product and is seeking retail outlets throughout
the country (see also Liquidity and Capital Resources below).

Revenues have also been generated in 2005 and 2004 in part from the sale of
the emergency CPR assistance device.  Sales for this product have remained
relatively constant over the past year or two, although the Company expects
that revenues for this product will increase in the near future, once the
marketing review of the Japanese market for this product is completed by
Itochu (see Liquidity and Capital Resources).

Additionally, the Company generated revenues in 2005 and 2004 related to
Superstat, a modified collagen hemostat, for which the Company has exclusive
distribution rights to the U.S. and foreign governments and militaries.
Revenues related to governmental orders of Superstat remained relatively
constant for the nine months ended September 30, 2005 compared to the nine
months ended September 30, 2004.  In addition to competition from other
companies that may offer alternative products, governmental orders from the
military are dependent on current foreign affairs and international conflicts
and the need for emergency products in the US military.

Cost of Sales:  During the nine months ended September 30, 2005, the Company
experienced a decrease in cost of sales of approximately $173,000 or
approximately 68% compared to the nine months ended September 30, 2004,
commensurate with the decrease in revenues for the same period.  Costs as a
percentage of sales were 66% for the nine months ended September 30, 2005
compared to 65% for the nine months ended September 30, 2004.  Costs as a
percentage of sales are expected to be slightly less than in the past due to
the expected increase in sales in foreign markets and the corresponding
reduced manufacturing costs overall in those markets. The significant
components of the Company's cost of sales include actual product cost,
including outsourced manufacturing and packaging, freight and shipping, and
royalties paid on revenues generated.

Operating Expenses: During the nine months ended September 30, 2005, the
Company experienced a decrease in general and administrative expenses of
approximately $351,000 or approximately 36% compared to the nine months ended
September 30, 2004, primarily due to a significant amount of outside
consulting, legal and other professional fees that were incurred during the
third quarter of 2004.

The Company has recently hired a Director of Manufacturing and a Director of
Business Development and expects, in the near future, to incur additional
operating costs related to this and the hiring of marketing and production
personnel for the increased business that is expected during late 2005 related
to the increased demand for the environmental mask and the finalization of the
Itochu agreement described below in the Liquidity and Capital Resources
section.  The significant components of our operating expenses include
salaries and wages, consulting and other professional services, product and
liability insurance, travel and office rent.

Research and development: Although not significant for the periods presented,
the Company expects research and development costs to increase somewhat in the
future because management intends to bring additional products to market
during the next year.  Future research and development costs for testing,
validation and FDA filings for these potential new products are estimated to
range from $50,000 to $60,000 during the next twelve months.

<PAGE>
<PAGE> 12

The Company spent approximately $44,000 during the nine months ended September
30, 2005, for additional molds required for one of its new products, ELVIS
(Emergency Life-Support Ventilation and Intubation System).  An additional
$30,000 to $40,000 may also be required for the production of molds for other
potential new products.  The significant components of the Company's research
and development costs ordinarily include prototype development and materials,
governmental filings and laboratory testing.

Liquidity and Capital Resources
-------------------------------
The Company has accumulated a deficit of $10,383,099 as of September 30, 2005,
resulting from development stage and continued losses since inception.
Consequently, the Company's ability to continue as a going concern may be
dependent upon the success of management's ongoing business plans which, as
explained below, include a) continued product development efforts, b)
continuing efforts to increase its product sales in the U.S. and
internationally, and c) obtain additional equity financing, if needed. For
this and other reasons, our auditors for our most recent fiscal year ended
December 31, 2004, expressed substantial doubt in their report as to our
ability to continue operating as a going concern.

The Company currently does not have and is not presently able to generate
sufficient net cash inflows from operations to sustain its business efforts as
well as to accommodate its growth plans.  It is management's intent to seek to
create additional revenues through the development and sales of its emergency
respiration equipment and its environmental masks through potential
distribution agreements currently being negotiated.

The Company issued 819,500 shares of common stock through the exercise of
common stock warrants during the first nine months of 2005, for total proceeds
of $243,625.  In addition, the Company issued an additional 2,982,600 shares
of common stock subsequent to September 30, 2005, also through the exercise of
common stock warrants, for total cash proceeds of $886,900.  The Company may
receive additional funds of up to approximately $264,000 through the exercise
of common stock warrants currently remaining outstanding.

With the funds raised during 2005 and 2004, the Company intends to bring
additional products to market during the next year, including the breathing
circuit filters, the ELVIS BVM bag, and the continued increase in production,
marketing and development of the personal environmental masks as previously
described.  The Company has recently retained the services of two consultants
to oversee final mold design, manufacturing and assembly of the ELVIS BVM bag
and to initiate FDA approval.  The estimated expense for this testing,
validation and FDA filings for ELVIS will be approximately $35,000. The
commission of molds for the ELVIS BVM bag will require an additional
approximate amount of $20,000 to $30,000 over the next few months.

Cash used by our operating activities for the periods ended September 30, 2005
and 2004 was funded primarily by the exercise of common stock warrants.

The Company is continuing to focus on a marketing-driven sales effort of its
medical products and the environmental masks and associated filters,
particularly in the Asian markets, to increase revenues that will ultimately
cover total expenditures.

<PAGE>
<PAGE> 13

During early 2005, the Company entered into a non-exclusive distribution
agreement with 2H Distributors, a California-based company, to distribute the
Company's environmental masks to both retail and wholesale market segments in
the United States and internationally.  2H Distributors has recently begun
ordering an increased amount of environmental masks and is continually
marketing the product and seeking retail outlets throughout the country.
Their wholesale marketing plans entail forming partnerships with a number of
consumer products distributors in Southeast Asian markets such as Vietnam and
Thailand.

In September 2004, the Company announced that it had been awarded a Prototype
Development/Testing/Evaluation Grant (PDT&E) to develop a testing protocol for
filter media on behalf of the U.S. Military. As part of this project, the
Company tested their licensed nano-enhanced filter media at Edgewood Chemical
Biological Center in Edgewood, Maryland. The original study funded by the
grant comprised protocols or tests to evaluate the Company's filter media
efficacy against four different contaminants.  As a result of the successful
completion of this testing phase, the Company was requested by the United
States military to test its filter media against a number of additional
contaminants.  This final phase of testing was completed during May 2005.  As
a result of these successful tests, the U.S. military is currently introducing
the Company's technology to companies that manufacture filters for various
military applications with the aim of having them incorporate the technology
in their filter applications.  The Company would also expect to sub-license
its nano-enhanced filter media to a number of Department of Defense approved
manufacturers to develop and/or enhance existing filtration products that are
currently used by the U.S. Air Force, Army and Navy, as well as to commence
development of new product applications that will serve to better protect U.S.
Military personnel.

In late 2004, the Company entered into an exclusive, long-term agreement with
Itochu Techno Chemical, Inc. (Itochu), a Japanese corporation, whereby Itochu
will distribute the Company's Respaide, Vapor Isolation Valve and Series One
Breathing Circuit Filter products in Japan, once their final assessment of the
overall market for the Company's products is completed.   The agreement
terminates on May 31, 2008, but can be extended for an additional three-year
period.  The agreement also allows for Itochu to form sub-distribution
agreements with other medical product companies, with the Company's approval,
to promote the sale of the Company's products in Japan.

During early 2005, and in conjunction with Itochu's partner/affiliate, Senko
Medical Instruments Mfg. Co. Ltd (one of Japan's leading medical products
distributors), Itochu has conducted a marketing review of the Company's
products.  This marketing review is required by Koseisho (Ministry of Health
and Welfare, similar to the United States FDA) and mandates that companies who
have been granted a certificate of import and a certificate of sale comply
fully with Japanese regulations concerning medical products.  The marketing
review will enable Itochu to make initial introductions of the products to
potential customers in Japan, to determine the potential size of the market in
Japan, and to allow the Company and Itochu to establish minimum purchase
requirement quantities applicable to the agreement for each annual period.

The Company has shipped a number of sample orders, and has modified its
products at the request of Itochu, to conform to Japanese medical product
standards.  These modifications necessitated minor but time consuming
alternations to existing molds.  As a result, this process has caused delays
in the commencement of shipping commercial orders to Itochu and its
distribution partners.  The Company has now completed all of the modifications
requested by its Japanese partners and is now awaiting final validation and

<PAGE>
<PAGE> 14

confirmation of the last round of modifications to the products, following
which the Company expects to initiate commercial shipments to Japan.

Management intends to seek to create additional revenues through the
development and sales of the Company's emergency respiration equipment and
sales of its environmental masks through potential distribution agreements
currently being negotiated in Taiwan and Japan, and to rely upon additional
equity financing, if required, to sustain operations until revenues are
adequate to cover the costs.  However, management can offer no assurance with
respect to its ability to create additional revenues, obtain additional equity
financing or execute its long-term business plans.

During its current fiscal year 2005, the Company expects that it will be able
to continue measures that will (i) reduce unnecessary cash outflows, and (ii)
increase revenues through our improved marketing efforts.

The Company's future business model is intended to be cost-efficient and will
emphasize:  (1) in-house research and development;  (2) accumulation of
intellectual property assets;  (3) ownership of key production equipment; and
(4) outsourcing of all manufacturing, distribution, warehousing, and order
fulfillment. Accordingly, the Company benefits from low overhead, as well as
the pricing advantages inherent in proprietary specialty products.

The Company has recently experienced a sharp increase in orders for its
environmental masks from a number of medical product distributors in the
United States and abroad, as previously discussed.  At the present time, the
Company is expanding its production facilities and has recently purchased
various new equipment in order to produce a sufficient amount of masks to meet
the current surge in demand which the Company believes is due to the growing
threat of a possible avian flu pandemic.  The Company plans to further
increase its production facility capabilities as the demand dictates.  The
Company is also working on expanding its production capabilities at its
facility in Taipei, Taiwan, where the mask shells are produced.

As previously discussed, our independent auditors for our most recent fiscal
year ended December 31, 2004, expressed substantial doubt in their report as
to our ability to continue operating as a going concern.

Impact of Inflation
-------------------
At this time, we do not anticipate that inflation will have a material impact
on our current or future operations.

Critical Accounting Policies and Estimates
------------------------------------------
Except with regard to the estimated useful lives of patents and acquired
technology, the Company does not employ any critical accounting policies or
estimates that are either selected from among available alternatives or
require the exercise of significant management judgment to apply or that if
changed are likely to materially affect future periods.  Management reviews
the carrying value of the technology assets annually for evidence of
impairment and considers, based on its current marketing activities, plans and
expectations, and the perceived effects of competitive factors and possible
obsolescence, whether any write-downs should be taken or whether the estimated
useful lives should be shortened.

<PAGE>
<PAGE> 15

Recent Accounting Pronouncements
--------------------------------

In December 2004, the Financial Accounting Standards Board (FASB) issued SFAS
No. 123 (Revised 2004), Share-Based Payment (SFAS 123R). SFAS 123R requires
that compensation cost related to share-based employee compensation
transactions be recognized in the financial statements. Share-based employee
compensation transactions within the scope of SFAS 123R include stock options,
restricted stock plans, performance-based awards, stock appreciation rights
and employee share purchase plans. The Company presently accounts for any
stock-based employee compensation under Accounting Principles Board (APB)
Opinion No. 25, the effect of which has not been significant in recent periods
due to the absence of such compensation.  The provisions of SFAS 123R are
effective as of the first interim period that begins after December 15, 2005.
Accordingly, we will implement the revised standard no later than the first
quarter of fiscal year 2006, if applicable.

In December 2004, the FASB issued SFAS No. 153, Exchanges of Nonmonetary
Assets, an Amendment of APB Opinion No. 29, Accounting for Nonmonetary
Transactions.  The amendments made by SFAS 153 are based on the principle that
exchanges of nonmonetary assets should be measured based on the fair value of
the assets exchanged. Further, the amendments eliminate the narrow exception
in APB Opinion No. 29 for nonmonetary exchanges of similar productive assets
and replace it with a broader exception for exchanges of nonmonetary assets
that do not have commercial substance. The Statement is effective for
nonmonetary asset exchanges occurring in fiscal periods beginning after June
15, 2005. We do not presently expect to enter into any transactions that would
be affected by adopting SFAS 153 when effective.

In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error
Corrections, a Replacement of APB Opinion No. 20 and SFAS No. 3.  SFAS No. 154
replaces APB Opinion No. 20, Accounting Changes and SFAS No 3, Reporting
Accounting Changes in Interim Financial Statements and changes the requirement
for the accounting for and reporting of a change in accounting principles.
SFAS No. 154 applies to all voluntary changes in accounting principles.  It
also applies to changes required by an accounting pronouncement in the unusual
instance that the pronouncement does not include specific transition
provisions.  When a pronouncement includes specific transition provisions,
those provisions should be followed.  The provisions of SFAS No. 154 will be
effective for accounting changes made in fiscal year beginning after December
15, 2005.  We do not presently expect to make any accounting changes that
would be affected by the adoption of SFAS No. 154 that will have a material
impact on the Company's financial condition or operations in the foreseeable
future.



<PAGE>
<PAGE> 16
                             ITEM 3.
                       CONTROLS AND PROCEDURES

Our principal executive and principal financial officers have participated
with management in the evaluation of effectiveness of the controls and
procedures required by paragraph (b) of Rule 13a-15 or Rule 15d-15 under the
Exchange Act as of the end of the period covered by this report.  Based on
that evaluation, our principal executive and principal financial officers
believe that our disclosure controls and procedures (as defined in Rule 13a-
15(e) or Rule 15d-15(e) under the Exchange Act) are effective as of the end of
the period covered by the report.  There have been no changes in our internal
controls that have materially affected, or are reasonably likely to materially
affect, our internal controls over financial reporting during the period
covered by this report.

                              PART II
                         OTHER INFORMATION
                     ITEM 1 - LEGAL PROCEEDINGS

In the quarter ended September 30, 2005, Emergency Filtration Products, Inc.
(the "Company") completed a settlement agreement (the "Settlement Agreement")
to resolve two related legal actions.  The two actions, described more fully
in the Company's quarterly report on Form 10QSB for the period ended June 30,
2005, filed with the Commission on August 15, 2005, were pending in the United
States District Court for the District of Nevada, Case No. CV-S-04-0262-RCJ-
LRL ("First Action") and Case No. CV-S-04-1386-RLH-LRL ("Second Action"),
consolidated in Case No. CV-S-04-1386-RLH-LRL (the "Actions").

The disputes in the above actions concerned the ownership of an aggregate of
744,425 shares of the Company's common stock originally issued to China Bridge
Holdings Limited, a British Virgin Islands ("BVI") corporation ("China
Bridge"), during 1999 and 2000.

The Settlement Agreement provides for the limited mutual release of all
parties for claims which could have been asserted, arising from or related to,
directly or indirectly, the Actions described above.  The parties further
agreed to dismiss all claims pending in the Actions with prejudice, subject to
certain limitations.

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

  None.

           ITEM 3 - DEFAULTS BY THE COMPANY ON ITS SENIOR SECURITIES
  None.

           ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
  None.

           ITEM 5 - OTHER INFORMATION

Effective October 20, 2005, Sherman Lazrus resigned as interim CEO of the
Company.  Mr. Lazrus remains Chairman of the Board of Directors.  Douglas
Beplate, the Company's President, will continue as President and will remain
as the Company's principal executive officer.


<PAGE>
<PAGE> 17

           ITEM 6 - EXHIBITS

   Exhibit 31.1 - Certification of principal executive officer as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002

   Exhibit 31.2 - Certification of principal financial officer as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002

   Exhibit 32.1 - Certification of principal executive officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002

   Exhibit 32.2 - Certification of principal financial officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002



                                SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned thereunto duly
authorized.

  Emergency Filtration Products, Inc.


 Date: November 14, 2005            By: /s/Douglas K. Beplate
                                    Douglas K. Beplate, President

 Date: November 14, 2005            By: /s/Steve M. Hanni
                                    Steve M. Hanni, Chief Financial Officer